TrialInternational journal of clinical oncology2013

A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.

Yasuhiro Suzuki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.